Feasibility and Safety of Systemic rAAV9-h NAGLU Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and Immunological Assessments in Primates
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
No treatment is currently available for mucopolysaccharidosis (MPS) IIIB, a neuropathic lysosomal storage disease caused by autosomal recessive defect in α-N-acetylglucosaminidase (NAGLU). In anticipation of a clinical gene therapy treatment for MPS IIIB in humans, we tested the rAAV9-CMV-hNAGLU vector administration to cynomolgus monkeys (n=8) at 1E13 vg/kg or 2E13 vg/kg via intravenous injection. No adverse events or detectable toxicity occurred over a 6-month period. Gene delivery resulted in persistent global central nervous system and broad somatic transduction, with NAGLU activity detected at 2.9-12-fold above endogenous levels in somatic tissues and 1.3-3-fold above endogenous levels in the brain. Secreted rNAGLU was detected in serum. Low levels of preexisting anti-AAV9 antibodies (Abs) did not diminish vector transduction. Importantly, high-level preexisting anti-AAV9 Abs lead to reduced transduction in liver and other somatic tissues, but had no detectable impact on transgene expression in the brain. Enzyme-linked immunoabsorbent assay showed Ab responses to both AAV9 and rNAGLU in treated animals. Serum anti-hNAGLU Abs, but not anti-AAV9 Abs, correlated with the loss of circulating rNAGLU enzyme. However, serum Abs did not affect tissue rNAGLU activity levels. Weekly or monthly peripheral blood interferon-γ enzyme-linked immunospot assays detected a CD4(+) T-cell (Th-1) response to rNAGLU only at 4 weeks postinjection in one treated subject, without observable correlation to tissue transduction levels. The treatment did not result in detectable CTL responses to either AAV9 or rNAGLU. Our data demonstrate an effective and safe profile for systemic rAAV9-hNAGLU vector delivery in nonhuman primates, supporting its clinical potential in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 2×
“…showed that the loss of FIX and concurrent increase in serum ALT were correlated with a T cell response to AAV8 capsid in two patients receiving a high dose of the vector at 8 and 9 weeks pi, suggesting that hepatic damage by cytotoxic T cells was the cause of FIX loss (Nathwani et al., 2011).”
BackgroundResultAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490 · cited 1×
“…of novel AAV serotypes, including the recently recognized trans-BBB neurotropic AAV serotype 9 (AAV9) (Duque et al., 2009; Foust et al., 2009; Zincarelli et al., 2008), has provided invaluable tools for efficient CNS gene delivery to treat neurological diseases, especially diseases such as…”
BackgroundIntravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 2×
“The characterization of novel AAV serotypes, including the recently recognized trans-BBB neurotropic AAV serotype 9 (AAV9) (Duque et al., 2009; Foust et al., 2009; Zincarelli et al., 2008), has provided invaluable tools for efficient CNS gene delivery to treat neurological diseases, especially…”
BackgroundKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“…and nonneuronal cells in the CNS in numerous gene therapy studies, with demonstrated therapeutic benefits in treating neurological diseases (Daya and Berns, 2008), including MPS and other LSDs, in animal models (Fu et al., 2002, 2003, 2007, 2011; Heuer et al., 2002; Desmaris et al., 2004;…”
BackgroundDuque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501 · cited 3×
“The recently demonstrated capability of AAV9 to efficiently cross the BBB has proven a valuable tool for therapeutic gene delivery to the CNS in a broad range of animal species (Duque et al., 2009; Foust et al., 2009, 2010; Bevan et al., 2011; Fu et al., 2011; Gray et al., 2011).”
BackgroundInfluentialWorgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402 · cited 1×
“Multiple phase I clinical trials have been completed using rAAV gene delivery approaches in patients with neurological disorders (McPhee et al., 2006; Kaplitt et al., 2007; Worgall et al., 2008; Marks et al., 2010; Mittermeyer et al., 2012).”
BackgroundBevan, A. K., Duque, S., Foust, K. D., Morales, P. R., Braun, L., Schmelzer, L., Chan, C. M., McCrate, M., Chicoine, L. G., Coley, B. D., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.157 · Cited by 337
Zhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291 · cited 1×
“Furthermore, recent studies demonstrate that additional novel AAV serotypes share the trans-BBB neurotropism of AAV9, and some of these are nonhuman serotypes, which may exhibit a lower prevalence of neutralizing Ab in the human population (Zhang et al., 2011).”
BackgroundThe cryptic life style of adenoassociated virus
Berns, K. I., & Linden, R. M. (1995) · BioEssays · doi:10.1002/bies.950170310 · Cited by 268 · cited 1×
“The adeno-associated virus (AAV) vector system offers important advantages as a gene delivery tool for treating a great variety of diseases, including a broad tissue tropism and absence of known pathogenesis in humans (Berns and Linden, 1995).”
BackgroundImmune responses to AAV in a phase I study for Canavan disease
McPhee, S. W. J., Janson, C. G., Li, C., Samulski, R. J., Camp, A. S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A., et al. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.885 · Cited by 241
Mingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112
McCarty, D. M., DiRosario, J., Gulaid, K., Muenzer, J., & Fu, H. (2009) · Gene Therapy · doi:10.1038/gt.2009.85 · Cited by 105 · cited 1×
“…(Daya and Berns, 2008), including MPS and other LSDs, in animal models (Fu et al., 2002, 2003, 2007, 2011; Heuer et al., 2002; Desmaris et al., 2004; Liu et al., 2005; Fraldi et al., 2007; Sands and Haskins, 2008; McCarty et al., 2009; Baek et al., 2010; Heldermon et al., 2010; Ruzo et al., 2012).”
Self-citation
Cited by
Tabebordbar, M., Lagerborg, K. A., Stanton, A., King, E. M., Ye, S., Tellez, L., Krunnfusz, A., Tavakoli, S., Widrick, J. J., Messemer, K. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.028 · Cited by 506
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
“The ADA titer included neutralizing antibodies (NAb) against NAGLU, and these NAb’s caused a depletion of endogenous NAGLU in the normal primates (Murrey et al., 2014).”
BackgroundMethodTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Metadata
- Authors
- Murrey, D. A., Naughton, B. J., Duncan, F. J., Meadows, A. S., Ware, T. A., Campbell, K. J., Bremer, W. G., Walker, C. M., Goodchild, L., Bolon, B., La Perle, K., Flanigan, K. M., McBride, K. L., McCarty, D. M., & Fu, H.
- Venue
- Human Gene Therapy Clinical Development
- Publisher
- SAGE Publications
- Published
- 2014-06
- Volume
- 25
- Issue
- 2
- Pages
- 72-84
- ISSN
- 2324-8637 (ISSN-L)
- 2324-8645
- OpenAlex
- W1747533618
- Cited by
- 88
- References
- 17
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.